UBS raises target to USD 735 for Madrigal Pharmaceuticals stock

Published on 10/20/2026 at 22:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Madrigal reports third-quarter results November 3, 2026. Madrigal Pharmaceuticals stock costs EUR 416.35 on October 20, 2026 at 10:03 p.m. CEST.

Analyst target and reporting date

UBS raised its Madrigal target to USD 735.00 from USD 669.00 on October 14, 2026.
Second-quarter Rezdiffra net sales reached USD 364.3 million, up 71.0 percent year over year.
Madrigal Pharmaceuticals stock was trading at EUR 416.35 at Lang & Schwarz on October 20, 2026 at 10:03 p.m. CEST.
Third-quarter 2026 results are scheduled for November 3, 2026.

MDGL, US5588681057, Illustration mit AI erstellt.

Madrigal Pharmaceuticals (US5588681057) drew a fresh analyst target on October 14, 2026, when UBS raised its price objective to USD 735.00 from USD 669.00 while keeping a Buy rating, as Markets Insider reported. Madrigal Pharmaceuticals was trading at EUR 416.35 at Lang & Schwarz on October 20, 2026 at 10:03 p.m. CEST.

UBS lifts the valuation bar

The UBS move places a USD 66.00 increase between the previous and new target. The firm also lifted its estimated probability of success for Madrigal's F4 program to 60.00 percent from 20.00 percent, according to Investing.com. That assessment is tied to the ongoing F4 Outcomes trial rather than to a new commercial announcement.

Rezdiffra revenue reached USD 364.3 million

Madrigal's second-quarter 2026 Rezdiffra net sales totaled USD 364.3 million, a 71.0 percent year-over-year increase. The figure exceeded the USD 350.85 million consensus cited by Investing.com, giving investors a concrete measure of commercial execution before the next report.

What does November 3 add?

Madrigal announced on October 20, 2026 that it will release third-quarter 2026 financial results on November 3, 2026, before the U.S. market opens, with an 8:00 a.m. Eastern Time webcast. Yahoo Finance carried the company release. The next report will therefore test whether the 71.0 percent second-quarter growth rate carried into the third quarter.

Nasdaq range frames the stock

On Nasdaq, MDGL was last at USD 467.54 on October 20, 2026 at 4:00 p.m. ET. Its 52-week range was USD 393.61 to USD 615.00, while market capitalization stood at USD 10.8 billion and the trailing P/E was negative 36.27. The stock sat 23.98 percent below its 52-week high and 18.78 percent above its 52-week low.

Price and business facts

Madrigal is a biopharmaceutical company focused on MASH treatments, led by Rezdiffra and its Phase 3 F4c outcomes trial, according to the company's investor-relations page. The scheduled November report offers the next dated checkpoint for sales growth, expenses and clinical progress.

Stock position

The euro quote remained the immediate market marker for German investors after the Xetra session. The company-specific picture combines a USD 735.00 UBS target, USD 364.3 million in second-quarter Rezdiffra sales and the November 3, 2026 reporting date.

Madrigal Pharmaceuticals was trading at EUR 416.35 at Lang & Schwarz on October 20, 2026 at 10:03 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Madrigal Pharmaceuticals stock.